Biktarvy costs about $4,216 for a 30-day supply at retail price, making it one of the most expensive daily medications in the United States. That works out to roughly $50,000 a year. The price reflects a combination of patent-protected exclusivity, expensive newer drug components, and the lack of any generic competition.
No Generic Competition Until at Least 2032
The single biggest reason Biktarvy costs what it does is that Gilead Sciences holds multiple patents on the drug, and no generic version has been approved by the FDA. The earliest patents don’t expire until August 2032, with additional patents extending through November 2036. That gives Gilead over a decade of market exclusivity from the drug’s 2018 approval, during which no competing manufacturer can legally produce a cheaper copy.
This is standard for brand-name drugs in the U.S., but it hits especially hard with HIV medications because patients take them every day for life. Without generic alternatives, there’s no price pressure from competitors, and Gilead can set the price based on what insurers and government programs will pay rather than what manufacturing actually costs.
A More Expensive Drug Component Inside
Biktarvy is a three-drug combination pill, and one of its key ingredients is a newer, safer form of tenofovir called tenofovir alafenamide (TAF). This replaced an older version called tenofovir disoproxil fumarate (TDF), which is now available as a cheap generic. TAF causes less kidney damage and fewer bone fractures. Over five years, using the older version instead of TAF would lead to an estimated 25 additional cases of kidney failure and over 2,000 additional fractures among U.S. users.
Those safety improvements come at a steep premium. The annual cost of TAF-based medications runs around $16,000 per year, compared to roughly half that for the older generic version. A cost-effectiveness analysis found that the price markup of TAF over generic TDF would only be justified at about $370 per year if society uses a standard willingness-to-pay threshold of $100,000 per quality-adjusted life year. In other words, the clinical benefits of TAF are real but modest for most people, while the price difference is enormous.
Clinical Performance Justifies Premium Positioning
Gilead prices Biktarvy as a best-in-class treatment, and the clinical data supports its effectiveness. In real-world follow-up studies over three years, 97% of both new and treatment-experienced patients maintained undetectable viral loads. Perhaps more notably, zero cases of treatment-emergent resistance were observed across multiple studies, including among patients who experienced temporary viral rebounds. A 93% resuppression rate was seen in those cases.
That resistance profile matters because if HIV develops resistance to a medication, the patient loses that drug as an option permanently. Biktarvy’s high barrier to resistance means fewer treatment switches over a lifetime, which in theory reduces long-term costs. Gilead uses this data to justify the price to insurers and pharmacy benefit managers, positioning Biktarvy not just as effective but as the safest long-term bet.
How U.S. Drug Pricing Inflates the Cost
Biktarvy’s price is also a product of how the American pharmaceutical market works. The U.S. does not negotiate drug prices the way most other countries do (though Medicare is beginning to negotiate on a limited number of drugs). Gilead sets a list price, then negotiates confidential rebates with insurance companies and pharmacy benefit managers. The $4,216 retail price is the sticker price before those rebates, so what insurers actually pay is lower, but the full amount still determines what uninsured patients and those in the deductible phase of their insurance owe.
Biktarvy generated over $12 billion in annual revenue for Gilead in recent years, making it one of the top-selling drugs in the world. That revenue stream creates little incentive to lower the price voluntarily, especially while patent protection holds.
What You Actually Pay Depends on Coverage
Under Medicare Part D, Biktarvy is typically classified as a Tier 5 specialty drug, defined as costing $950 or more per month. That means you pay a percentage of the drug’s cost (co-insurance) rather than a flat copay. Depending on your specific plan, that co-insurance ranges from 26% to 33% after your deductible, which could mean over $1,000 per month out of pocket before hitting catastrophic coverage limits.
Private insurance varies widely. Many commercial plans cover Biktarvy but place it on high-cost specialty tiers with significant cost-sharing. Some employer plans and Medicaid programs cover it with lower out-of-pocket costs.
Gilead runs a patient assistance program called Advancing Access that provides the drug at no cost to qualifying patients. The company doesn’t publicly list income thresholds on its main website, but eligibility information is available through their dedicated access line. Separately, Gilead offers copay assistance cards for commercially insured patients that can reduce monthly costs significantly, though these typically don’t apply to government insurance like Medicare or Medicaid.
The 340B Program and Ryan White Safety Net
For uninsured or underinsured patients in the U.S., the federal 340B drug pricing program requires manufacturers like Gilead to sell medications at steep discounts to qualifying health centers, including many HIV clinics. The Ryan White HIV/AIDS Program also funds medication access for people who can’t afford treatment. These programs mean that most people with HIV in the U.S. can access Biktarvy regardless of ability to pay, but the system relies on a patchwork of programs rather than an affordable list price.
The core issue remains: Biktarvy is expensive because Gilead holds exclusive patents on a highly effective drug in a market that allows manufacturers to set prices without direct government price controls. That dynamic won’t meaningfully change until generic versions become available, with the earliest possible entry still years away.